New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))); influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))); influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))); influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 (bvr-1b))) - suspension for injection - 60 mcg/0.5ml - active: influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))) influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))) influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))) influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 (bvr-1b))) excipient: calcium chloride dihydrate dibasic sodium phosphate monobasic potassium phosphate monobasic sodium phosphate potassium chloride sodium chloride water for injection - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. afluria quad vaccine is indicated for use in persons aged 3 years and over. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - influenza virus a/hong kong/4801/2014 (h3n2) - like strain 15ug (a/hong kong/4801/2014 (x-263b)); influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/singapore/gp1908/2015 (ivr-180)); influenza virus b/brisbane/60/2008 - like strain 15ug (b/brisbane/46/2015) - suspension for injection - 0.5 ml - active: influenza virus a/hong kong/4801/2014 (h3n2) - like strain 15ug (a/hong kong/4801/2014 (x-263b)) influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/singapore/gp1908/2015 (ivr-180)) influenza virus b/brisbane/60/2008 - like strain 15ug (b/brisbane/46/2015) excipient: calcium chloride dihydrate dibasic sodium phosphate monobasic potassium phosphate monobasic sodium phosphate dihydrate potassium chloride sodium chloride water for injection - fluvax is indicated for the prevention of influenza caused by infuenza virus, types a and b. for the southern hemisphere 2017 season, the vaccine is indicated for use only in persons aged 5 years and over

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 100mg;  ;   - film coated tablet - 100 mg - active: lacosamide 100mg     excipient: colloidal silicon dioxide crospovidone hyprolose   magnesium stearate microcrystalline cellulose opadry yellow 85f38040 - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 150mg;  ;   - film coated tablet - 150 mg - active: lacosamide 150mg     excipient: colloidal silicon dioxide crospovidone hyprolose   magnesium stearate microcrystalline cellulose opadry tan 85f27043 - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 200mg;  ;   - film coated tablet - 200 mg - active: lacosamide 200mg     excipient: colloidal silicon dioxide crospovidone hyprolose   magnesium stearate microcrystalline cellulose opadry blue 85f30675 - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 50mg;  ;   - film coated tablet - 50 mg - active: lacosamide 50mg     excipient: colloidal silicon dioxide crospovidone hyprolose   magnesium stearate microcrystalline cellulose opadry purple 85f20249 - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 10 mg/ml - solution for injection - 200 mg/20ml - active: lacosamide 10 mg/ml excipient: hydrochloric acid sodium chloride water for injection - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. vimpat (lacosamide) injection for intravenous infusion is indicated when oral administration is temporarily not feasible. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - lacosamide 10 mg/ml;   - oral solution - 10 mg/ml - active: lacosamide 10 mg/ml   excipient: acesulfame potassium carmellose sodium citric acid glycerol macrogol 4000 mask flavour 501521 t purified water sodium chloride sodium methyl hydroxybenzoate sorbitol as crystallizing liquid strawberry flavour 501440t - monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - mesalazine 500mg;   - enteric coated tablet - 500 mg - active: mesalazine 500mg   excipient: colloidal silicon dioxide crospovidone hypromellose povidone k90   methacrylic acid - methyl metacrylate copolymer (1:2) iron oxide yellow macrogol 6000   magnesium stearate   microcrystalline cellulose povidone purified talc titanium dioxide triethyl citrate - the treatment of crohn's disease localised to the colon.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - influenza virus a (h1n1) haemagglutinin 7.5ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))); influenza virus a (h3n2) haemagglutinin 7.5ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))); influenza virus b (victoria) haemagglutinin 7.5ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))); influenza virus b (yamagata) haemagglutinin 7.5ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 (bvr-1b))) - suspension for injection - 30 mcg/0.25ml - active: influenza virus a (h1n1) haemagglutinin 7.5ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))) influenza virus a (h3n2) haemagglutinin 7.5ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))) influenza virus b (victoria) haemagglutinin 7.5ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))) influenza virus b (yamagata) haemagglutinin 7.5ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 (bvr-1b))) excipient: calcium chloride dihydrate dibasic sodium phosphate monobasic potassium phosphate monobasic sodium phosphate potassium chloride sodium chloride water for injection - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. afluria quad junior vaccine is indicated for use in children aged 6 months to 35 months inclusive. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.